PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
29.77%
Some net income increase while AXSM is negative at -58.61%. John Neff would see a short-term edge over the struggling competitor.
-0.50%
Both reduce yoy D&A, with AXSM at -0.17%. Martin Whitman would suspect a lull in expansions or intangible additions for both.
15.92%
Deferred tax of 15.92% while AXSM is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
0.65%
Less SBC growth vs. AXSM's 27.46%, indicating lower equity issuance. David Dodd would confirm the firm still retains key staff.
-31.26%
Negative yoy working capital usage while AXSM is 138.22%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
59.84%
Lower AP growth vs. AXSM's 183.56%, indicating prompt payments. David Dodd would confirm no lost opportunity in interest-free credit if expansions are underfunded.
-40.45%
Negative yoy usage while AXSM is 0.31%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-15.92%
Negative yoy while AXSM is 4252.04%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
32.67%
Operating cash flow growth at 75-90% of AXSM's 43.30%. Bill Ackman would recommend further refinements to match competitor’s CFO gains.
100.00%
CapEx growth well above AXSM's 98.11%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Investing outflow well above AXSM's 98.11%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
No Data
No Data available this quarter, please select a different quarter.
-58.30%
Both yoy lines negative, with AXSM at -96.61%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.